Premium
Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Author(s) -
LaCasce Ann S.,
Bociek R. Gregory,
Sawas Ahmed,
Caimi Paolo,
Agura Edward,
Matous Jeffrey,
Ansell Stephen M.,
Crosswell Howland E.,
IslasOhlmayer Miguel,
Behler Caroline,
Cheung Eric,
ForeroTorres Andres,
Vose Julie,
O’Connor Owen A.,
Josephson Neil,
Wang Yinghui,
Advani Ranjana
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16499
Subject(s) - brentuximab vedotin , bendamustine , salvage therapy , medicine , oncology , refractory (planetary science) , hodgkin lymphoma , lymphoma , chemotherapy , rituximab , biology , astrobiology
F., Wilson, R.K., Ley, T.J. & Ding, L. (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 20, 1472–1478. Yuan, X.Q., Chen, P., Du, Y.X., Zhu, K.W., Zhang, D.Y., Yan, H., Liu, H., Liu, Y.L., Cao, S., Zhou, G., Zeng, H., Chen, S.P., Zhao, X.L., Yang, J., Zeng, W.J. & Chen, X.P. (2019) Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients. Journal of Translational Medicine, 17, 220.